V8 Peptides — Engineered Performance
Research Library
Research Peptide Documents in 2026: HHS, FDA and WADA Read
Research CompoundsRegulatory

Research Peptide Documents in 2026: HHS, FDA and WADA Read

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

What do the primary documents say about research peptide status in 2026? As read on 17 November 2026: an HHS notice (30 October 2026) announces a draft enforcement discretion policy for 503A compounding whose Appendix A names six peptides; FDA's 503A pages and July 2026 advisory-committee materials describe the compounding framework and the review of seven nominated peptides; and the WADA 2026 List names several peptides as prohibited in sport. This summarizes documents only and gives no legal conclusion or advice.

Searches for the regulatory status of research peptides in 2026 tend to return commentary built on other commentary. This article reads primary documents only and gives the date each was read (17 November 2026): a Notice of Availability published in the Federal Register by the Department of Health and Human Services on 30 October 2026 and the policy document it points to; the U.S. Food and Drug Administration's pages on section 503A bulk drug substances, its Category 2 page and its July 2026 Pharmacy Compounding Advisory Committee (PCAC) materials; and the World Anti-Doping Agency's 2026 Prohibited List. It adds one published FDA warning letter. It draws no legal conclusion, gives no advice, and does not say whether any particular activity is lawful. Law-firm and news summaries were not used as sources. The library's earlier overview is research peptide legal status in the US; this piece is a dated, document-by-document reading, and the documents may have changed since 17 November 2026.

V8 products are labeled for laboratory research use only. Nothing here describes any use outside a laboratory.

Document 1: the HHS notice of 30 October 2026

The Federal Register notice (91 FR 68526, document 2026-22192, docket HHS-OASH-2026-0496; pages 68526-68527; filed 28 October 2026) announces the availability of a draft "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances." Its summary states that the document describes the HHS Secretary's enforcement policy on the use of certain peptide bulk drug substances in compounding under section 503A of the Federal Food, Drug, and Cosmetic Act while the list of bulk drug substances that can be used under section 503A (the "503A bulks list") is developed through rulemaking. The notice says written comments could be submitted until two weeks after publication via regulations.gov, and the Federal Register docket record lists a comment period of 30 October to 14 November 2026. It states that the draft policy "does not establish any rights for any person and is not binding on HHS or the public," that HHS may revisit the policy "if, among other things, a safety signal or product quality issue arises," and that "FDA's future rulemakings may propose adding some or all of these peptides to the 503A bulks list."

The policy document linked from the notice describes compounding as a practice by a licensed pharmacist or physician and states that compounded drugs are not FDA-approved. It says HHS "does not intend to take enforcement action against a State-licensed pharmacy, Federal facility, or licensed physician compounding a drug product using a bulk drug substance in Appendix A" when a set of stated circumstances is present. Appendix A, as read on 17 November 2026, lists six substances: BPC-157, epitalon, KPV, MOTS-c, semax and TB-500. The circumstances listed include appearance in Appendix A, the identity described in Appendix B, characterization in a valid certificate of analysis, an original manufacturer registered with FDA under section 510, reporting of serious adverse events and product quality issues to FDA's MedWatch program, the label statement "This is a compounded drug product. Not for resale.," a single active ingredient, and compliance with other applicable FD&C Act requirements. Appendix B gives each peptide's identity (formula, molecular weight, sequence) and the document's stated justification and permitted forms.

Two points about scope are stated here as the document states them. First, the policy is written in terms of compounding by State-licensed pharmacies, Federal facilities and licensed physicians under section 503A, and its Appendix A is the list it applies to. Second, in its description of the policy, the HHS document says the Secretary determined that the policy "will discourage the continued, widespread use of certain research-use-only peptides supplied by foreign manufacturers that pose a safety risk" (the sentence continues beyond this quotation). That sentence is the document's own description of its aim; it is quoted for completeness and is not interpreted here. This article makes no statement about what either point means for any seller or buyer.

Document 2: the FDA 503A bulk drug substances page

FDA's page on bulk drug substances used in compounding under section 503A (read 17 November 2026) says state-licensed physicians and pharmacists that compound under section 503A "may only compound drug products using bulk drug substances" that: comply with an applicable USP or NF monograph if one exists; are components of FDA-approved drug products if no monograph exists; or appear on FDA's 503A bulks list if neither applies. It adds that bulk drug substances "must be accompanied by a valid certificate of analysis and must have been manufactured by an establishment registered with FDA," and that "the agency urges compounders to know your bulks supplier." The page describes three categories of nominated substances under an interim policy: category 1 (FDA does not intend to take action against a compounder for compounding with these substances, provided the guidance conditions are met), category 2 (FDA identified significant safety risks and does not adopt the category 1 policy) and category 3 (nominated with insufficient supporting information). It notes that a guidance document states the agency does not intend to place substances nominated on or after 7 January 2025 into these categories. The regulatory text of the 503A bulks list is 21 CFR 216.23(a) (eCFR, read 17 November 2026); it names six substances, and none is a peptide discussed in this article.

FDA's separate page "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks" (read 17 November 2026) places BPC-157, epitalon, KPV, MOTs-C, selank acetate, semax, thymosin-alpha 1 and "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" under the heading "Bulk drug substances nominated but withdrawn," described as substances "previously in category 2 of the interim policies" that "were withdrawn by the nominators." The HHS policy document's Appendix B uses different words: it states that BPC-157 was in Category 2 "from September 2023 until April 22, 2026," that TB-500 (like epitalon and semax) was in Category 2 "from September 29, 2023, until April 22, 2026," and that for each "neither the placement nor the removal changed" its status under section 503A. The two documents are reported side by side here without reconciling them.

Document 2b: FDA advisory committee materials, July 2026

A Federal Register notice of 16 April 2026 (91 FR 20465, document 2026-07361, docket FDA-2025-N-6895) announced a PCAC meeting on 23 and 24 July 2026 on bulk drug substances nominated for inclusion on the 503A bulks list. FDA's agenda document for the meeting (fda.gov/media/193342/download) lists for 23 July: BPC-157, KPV, TB-500 and MOTs-C (each as free base and acetate), and for 24 July: emideltide, epitalon and semax. FDA's event page (read 17 November 2026) states that advisory committees "make non-binding recommendations to the FDA." FDA's briefing documents for the meeting state, for both BPC-157 (media/193343) and TB-500 (media/193349), that "there is no applicable United States Pharmacopeia (USP) or National Formulary (NF) drug substance monograph" for the substance or its acetate form, "and neither is a component of an FDA-approved drug," and that FDA staff "believe the evaluation criteria weigh against placing" them on the 503A bulks list. The HHS policy document states that the PCAC "voted in favor of inclusion" for BPC-157 and "in favor of both forms" for TB-500, epitalon and semax. This article did not locate FDA minutes or a vote record for the meeting, so the votes are reported only as the HHS document describes them.

Document 3: the WADA 2026 Prohibited List

The 2026 Prohibited List states that it "shall come into effect on 1 January 2026" and is titled "World Anti-Doping Code International Standard." The text was read on 17 November 2026 from the English PDF posted on wada-ama.org (file 2026list_en_final_clean_september_2025.pdf), including its index. Section S0, "Non-approved substances," covers any pharmacological substance not addressed elsewhere in the List and with no current approval by a governmental regulatory health authority for use as a medicine in people (this is a paraphrase of the List's wording), and states that the class includes "but is not limited to BPC-157, 2,4-dinitrophenol (DNP)" and other examples. Section S2.2.3 lists growth hormone fragments such as AOD-9604 and hGH 176-191. Section S2.2.4 lists growth hormone releasing factors including CJC-1295, sermorelin and tesamorelin, and growth hormone secretagogues including ipamorelin. Section S2.3 lists "Thymosin-ß4 and its derivatives e.g. TB-500" among growth factors and growth factor modulators. Section S4.4.1 lists activators of AMP-activated protein kinase, with MOTS-c named as an example. The List states that S0 and S2 are "prohibited at all times (in- and out-of-competition)."

Side-by-side: where named peptides appear in these documents

The table records only what the documents above say about named compounds, as read on 17 November 2026. "Not listed" or "Not named" means the compound does not appear in that document's text; it says nothing about its status elsewhere.

CompoundHHS interim policy, Appendix AWADA 2026 List (named entry)Notes
BPC-157ListedS0, named as an exampleCategory 2 from Sept 2023 to 22 Apr 2026, per the HHS document
TB-500ListedS2.3, as a thymosin-β4 derivativeCategory 2 from 29 Sept 2023 to 22 Apr 2026, per the HHS document
KPVListedNot named—
AOD-9604Not listedS2.2.3, as a GH fragment—
MOTS-cListedS4.4.1, as an AMPK activatorReviewed at the 23 July 2026 PCAC meeting (FDA event page)
CJC-1295Not listedS2.2.4, as a GHRH analogue—
IpamorelinNot listedS2.2.4, as a GH secretagogue—
PT-141 (bremelanotide)Not listedNot namedFDA approval package for bremelanotide (NDA 210557) exists; not addressed in the compounding documents read
Selank, GHK-Cu, retatrutideNot listedNot named—

Compound background is in the BPC-157 research overview and the PT-141 research overview.

What FDA has said about "research use only" labelling

FDA publishes warning letters on fda.gov. One, MARCS-CMS 694608 dated 10 December 2024, issued by the Center for Drug Evaluation and Research under the subject "Unapproved New Drugs/Misbranded," states that, despite "FOR RESEARCH USE ONLY" statements on the labeling of the products it discusses, evidence obtained from the recipient's website "establishes that your products are intended to be drugs," because the claims it quotes indicate they are intended to address disease conditions and/or affect the structure or function of the body. The letter cites sections 505(a) and 301(d) of the FD&C Act. It is the agency's reasoning in one letter to one recipient about specific products and statements, reported as published and not as a general rule. FDA's regulation at 21 CFR 201.128, "Meaning of intended uses," states that intent "may be shown by labeling claims, advertising matter, or oral or written statements" and by "the circumstances surrounding the distribution of the article." Related reading on supplier evaluation: the earlier overview, red flags when buying research peptides and vetting a research peptide supplier.

A timeline of the dates in this article

DateEventSource
10 December 2024FDA warning letter MARCS-CMS 694608 issuedFDA
7 January 2025Substances nominated on or after this date are not placed in interim categoriesFDA 503A page
1 January 2026WADA 2026 Prohibited List takes effectWADA
16 April 2026Federal Register notice of the July PCAC meeting (91 FR 20465)Federal Register
22 April 2026End of the Category 2 period stated for BPC-157, TB-500, epitalon and semaxHHS policy document
23-24 July 2026PCAC meeting on seven nominated peptide substancesFDA agenda document
30 October 2026HHS notice published, 91 FR 68526Federal Register
14 November 2026Comment end date listed in the Federal Register docket recordFederal Register
17 November 2026Date these documents were read for this article—

Reading dates and drafts correctly

Three habits help when reading regulatory material. First, check the document type: a Notice of Availability for a draft policy is not a final rule, and this notice itself says the draft policy is not binding. Second, record the access date, because dockets, drafts and lists change; the Federal Register docket record for this notice lists a comment period ending 14 November 2026. Third, note which body issued each document: HHS, FDA and WADA are different bodies, and each document above speaks only for its issuer. For laboratory records, identity, purity and lot documentation are described in how to read a COA and on the COA page.

Limits of this article

This article reads the documents listed in the references and one warning letter. The WADA List was read in full, but only the entries named above are summarized; prohibited methods and sport-specific lists are not covered. FDA staff evaluations for peptides other than BPC-157 and TB-500 were not read. It does not cover state law, controlled-substance scheduling, import and customs rules, or foreign regulation. It does not assess whether any seller or activity complies with any law. The text of the current documents should be read directly using the references below. The V8 catalogue is on the shop page, supplied for laboratory research use only.

Frequently asked questions

What did HHS publish on 30 October 2026?

A Notice of Availability (91 FR 68526) for a draft enforcement discretion policy on 503A compounding using certain peptide bulk drug substances, with written comments invited until two weeks after publication on docket HHS-OASH-2026-0496.

Which peptides does Appendix A of the HHS policy list?

As read on 17 November 2026: BPC-157, epitalon, KPV, MOTS-c, semax and TB-500.

Is the HHS policy binding?

The notice states that the draft policy does not establish any rights for any person and is not binding on HHS or the public. It also says HHS may revisit it if a safety signal or product quality issue arises.

What does the HHS policy document say about research-use-only peptides?

It states that the Secretary determined the policy "will discourage the continued, widespread use of certain research-use-only peptides supplied by foreign manufacturers that pose a safety risk" (the sentence continues beyond this quotation). This article quotes that sentence and does not interpret it.

What are the three routes for a bulk drug substance under section 503A?

A USP or NF monograph, a component of an FDA-approved drug, or inclusion on FDA's 503A bulks list, according to FDA's page read 17 November 2026.

Which peptides does WADA name in the 2026 List?

Among compounds discussed here: BPC-157 under S0, AOD-9604 and hGH 176-191 under S2.2.3, CJC-1295 and ipamorelin under S2.2.4, thymosin-β4 derivatives such as TB-500 under S2.3, and MOTS-c under S4.4.1.

Do the FDA and WADA documents name the same compounds?

Partly. BPC-157, TB-500 and MOTS-c appear in both the HHS Appendix A and the WADA List; AOD-9604, CJC-1295 and ipamorelin appear in the WADA List but not in Appendix A. The table above records each entry.

Which peptides did the July 2026 FDA advisory committee meeting consider?

FDA's agenda document lists BPC-157, KPV, TB-500 and MOTs-C for 23 July 2026, and emideltide, epitalon and semax for 24 July 2026.

What did FDA say in the warning letter about research-only labels?

In one letter (10 December 2024), FDA stated that website claims established that the products discussed were intended to be drugs despite "FOR RESEARCH USE ONLY" labeling. This is the agency's reasoning in that letter only.

Does this article say whether anything is legal?

No. It reports what documents state, with dates, and draws no legal conclusion.

Related reading: Tirzepatide: FDA, HHS and WADA Documents Read, BPC-157 Regulatory Documents in 2026: A Dated Reading, BPC-157 and TB-500: US Regulatory Documents in 2026, PT-141 US Regulatory Status: A Primary-Source Summary.

References

  1. Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (notice of availability). Federal Register. 2026 Oct 30;91:68526-68527. Document 2026-22192. https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances (read 17 November 2026).
  2. Department of Health and Human Services. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (policy document, Appendices A and B). https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf (read 17 November 2026).
  3. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (page read 17 November 2026); Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (read 17 November 2026); 21 CFR 216.23 (eCFR, read 17 November 2026). fda.gov; ecfr.gov.
  4. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee, event page, and FDA Briefing Documents for BPC-157 (fda.gov/media/193343/download) and TB-500 (fda.gov/media/193349/download), read 17 November 2026.
  5. Food and Drug Administration. Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket. Federal Register. 2026 Apr 16;91:20465-20467. Document 2026-07361 (read 17 November 2026).
  6. World Anti-Doping Agency. The 2026 Prohibited List, World Anti-Doping Code International Standard. In force 1 January 2026. English PDF at wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf (text read 17 November 2026).
  7. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Warning letter MARCS-CMS 694608, 10 December 2024 (Unapproved New Drugs/Misbranded). fda.gov, Warning Letters (read 17 November 2026).
  8. U.S. Food and Drug Administration. Approval package for NDA 210557 (bremelanotide), approval date 21 June 2019. accessdata.fda.gov/drugsatfda_docs/nda/2019/210557Orig1s000Approv.pdf (read 17 November 2026).

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.